Avagenesis Corp. Receives Notice of Patent Allowance in Canada for Cell Isolation System

CALGARY, AB / ACCESSWIRE / September 25, 2015 / Avagenesis Corp. (“Avagenesis” or the “Company”) (TSX Venture: VVA), is pleased to announce that its licensed technology has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent application on adipose cell isolation technology. The Company anticipates the patent to be issued within 60 days.

Once that occurs, patents will have been issued on the Company’s licensed technology in a total of eight jurisdictions (the others being the United States, Australia, Singapore, Russia, Japan, South Korea and China). Avagenesis expects more patent issuances internationally over the next 18 months.

About Avagenesis Corp.

Avagenesis is a biotechnology company engaged in the commercialization of medical technologies for use in the practice of cosmetic surgery and regenerative medical aesthetics. Avagenesis’ development activities are focused on the complex task of efficiently isolating high quality, viable and potent adipose-derived adult stem cells and regenerative cells using patent-pending and patented bioprocessing and cell isolation technology. For licensing and strategic reasons, all patent registrations, FDA registrations and other regulatory certificates are arranged through an exclusive licensing agreement with a related and affiliated company.

Neither the Exchange nor its regulation services provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could,” “intend,” “expect,” “believe,” “will,” “projected,” “likely”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Avagenesis’ current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that Avagenesis may not successfully transition to a clinical stage company and the risk that Avagenesis may not successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Avagenesis. Avagenesis cautions the reader that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and Avagenesis is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Further Information

For further information, please contact:
Avagenesis Corp.
Alan Tam, CPA, CA
Chief Financial Officer
Telephone: (604) 377-7575

SOURCE: Avagenesis Corp.

ReleaseID: 432232